Nepal allows late-stage trials for Chinese mRNA vaccine candidate - Xinhua

1 minute read

Boxes of Walvax Biotechnology's messenger RNA (mRNA) vaccine against the coronavirus disease (COVID-19) are seen displayed at a trade fair in Shanghai, China April 16, 2021. China Daily via REUTERS

Register now for FREE unlimited access to Reuters.com

Aug 28 (Reuters) - Nepal has allowed China's Walvax Biotechnology (300142.SZ) to conduct phase 3 trials for the company's mRNA COVID-19 vaccine candidate in the country, China's official Xinhua news agency reported on Friday, citing a Nepal health official.

The ARCoV vaccine was jointly developed by China's Suzhou Abogen Biosciences, the Institute of Military Medicine under the Academy of Military Sciences and Walvax.

"We received a proposal from the Chinese company about a month ago seeking approval to conduct clinical trials," Pradip Gyanwali, executive chief of the Nepal Health Research Council, told Xinhua. (https://bit.ly/3gGk8FH)

"Access to vaccines will be easier if they are manufactured in Nepal."

Walvax and local partner Deurali-Janta Pharmaceutical Pvt Ltd will conduct the trials in Nepal on 3,000 people at BP Koirala Institute of Health Sciences, a government facility in the eastern city of Dharan, the report said.

Register now for FREE unlimited access to Reuters.com
Reporting by Juby Babu in Bengaluru; Editing by Devika Syamnath

Our Standards: The Thomson Reuters Trust Principles.